Maintenance of growth in cystic fibrosis despite reduction in pancreatic enzyme supplementation

Archives of Disease in Childhood

Volumn 78, Issue 4, 1998, Pages 377-378

  Lowdon, Jacqueline ^a   Goodchild, Mary C ^a   Ryley, Henry C ^a   Doull, Iolo J M ^a  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

Cystic fibrosis; Growth; Pancreatic enzyme dosage

Indexed keywords

PANCREAS ENZYME; TRIACYLGLYCEROL LIPASE;

ARTICLE; BODY HEIGHT; BODY WEIGHT; CALORIC INTAKE; CHILD; CHILD GROWTH; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DOSE RESPONSE; FAT INTAKE; HUMAN; PRIORITY JOURNAL;

EID: 0031915692     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.78.4.377     Document Type: Article

References (5)

1. Smyth RL, Ashley D, O'Hea U, et al. Fibrosing colonopathy in cystic fibrosis: results of a case-control study. Lancet 1995;346:1247-51.
2. FitzSimmons SC, Burkhart GA, Borowitz D, et al. High dose pancreatic enzyme supplements and fibrosing colonopathy in children with cystic fibrosis. N Engl J Med 1997; 336:1283-9.
3. Committee on the Safety of Medicines. Report of the Pancreatic Enzymes Working Party. London: Committee on the Safety of Medicines: Medicines Control Agency, 1995.
4. Paull AA, Southgate DAT, eds. McCance and Widowson's the composition of foods. London: HMSO, 1991.
5. van de Kamer JH, ten Bokkel Huinink H, Weyers HA. Rapid method for determination of fat in faeces. J Biol Chem 1949;177:347-55.